Skip to content

Neuroprotective Role of Erythropoietin in Perinatal Asphyxia

Erythropoietin in Perinatal Asphyxia: A Randomized Placebo Controlled Trial

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02002039
Enrollment
100
Registered
2013-12-05
Start date
2012-06-30
Completion date
2016-06-30
Last updated
2016-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perinatal Asphyxia

Keywords

Perinatal asphyxia, erythropoietin

Brief summary

Whether Erythropoietin improves the neurological outcomes of neonates with perinatal asphyxia.

Detailed description

will be a randomized trial

Interventions

DRUGErythropoietin

500 units /kg /day every other day for 5 doses

Sponsors

Sheri Kashmir Institute of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 6 Hours
Healthy volunteers
No

Inclusion criteria

* Babies with severe perinatal asphyxia with moderate to severe HIE in the immediate neonatal period

Exclusion criteria

* Babies with congenital malformations * Small for gestational age babies * Babies with chromosomal anomalies

Design outcomes

Primary

MeasureTime frame
Death or moderate or severe disability at 18-22 months of age18-22 months

Secondary

MeasureTime frameDescription
Disability18-22 monthsSevere disability was defined as GMFCS grade of level 3-5, hearing impairment requiring hearing aids, bilateral cortical visual impairment with no useful vision or Bayley Mental Development Index Score less than 70. Moderate disability was defined as Bayley Mental Developmental Index Score between 70-84 and any one of the following criteria: GMFCS grade of level 2, hearing impairment with no amplification or persistent seizure disorder.
Bayley psychomotor development index18-22 months months
Hearing loss at 18-22 months18-22 months

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026